| abstract |
The present invention provides a cell mediated by planned cell death 1 protein (PD-1) and lymphocyte activation 3 (LAG3) in interfering with PD-1 and / or LAG3 positive cells. Means and methods of suppression. The method may include contacting the cell with an antibody or a functional portion, derivative, and / or analog thereof, wherein the antibody or a functional portion, derivative, and / or analog thereof comprises an extracellular portion that can bind to PD-1 And a variable domain that can bind to the extracellular part of LAG3, thereby inhibiting the activity mediated by PD-1 and / or LAG3 in said cells. The present invention also provides an antibody or a variant thereof comprising a variable domain capable of binding to the extracellular part of PD-1 and a variable domain capable of binding to the extracellular part of LAG3. |